Basilea Pharmaceutica - Zevtera crosses key US regulatory hurdle
Basilea has announced the FDA approval of its second lead asset, Zevtera (ceftobiprole), for the treatment of severe bacterial infections (three...
359 Views
Basilea Pharmaceutica - Strong Cresemba traction triggers milestone payment
Continued strong sales of Cresemba, Basilea Pharmaceutica’s lead antifungal asset, in the Asia-Pacific region and China, has triggered the receipt...
240 Views
Basilea Pharmaceutica - From strength to strength
FY23 was another strong year for Basilea, marked by successive guidance beats and meaningful progress in fortifying its product pipeline. Revenues...
189 Views
Basilea Pharmaceutica - Strong close to FY23 with another milestone payment
Basilea has announced receipt of its first sales-related milestone (for an undisclosed amount) from distribution partner Knight Therapeutics. The...
340 Views
Basilea Pharmaceutica - Antibiotic addition to further replenish pipeline
Basilea has announced a preclinical antibiotic programme asset purchase agreement, aligning with management’s pre-emptive efforts to refill its...
162 Views